血清miR-1298-5p表达对晚期非小细胞肺癌患者免疫治疗效果及预后的评估价值OA
The value of serum miR-1298-5p expression in evaluating efficacy and prognosis of immunotherapy in patients with advanced non-small cell lung cancer
目的 探讨血清微RNA-1298-5p(microRNA-1298-5p,miR-1298-5p)表达对晚期非小细胞肺癌(advanced non-small cell lung cancer,aNSCLC)患者免疫治疗效果及预后的评估价值.方法 选取2022年1月至2024年4月于赣州市人民医院接受免疫治疗的aNSCLC患者120例纳入aNSCLC组,同期来院健康体检者35人纳入对照组,aNSCLC患者根据3个月免疫治疗效果分为无效组和有效组,随访1年根据预后分为死亡组和存活组.采用多因素非条件Logistic回归分析血清miR-1298-5p表达与aNSCLC患者免疫治疗预后的关系,受试者操作特征曲线分析血清miR-1298-5p表达对aNSCLC患者免疫治疗效果及预后的预测效能.结果 aNSCLC组患者的血清miR-1298-5p表达显著低于对照组(P<0.05).120例aNSCLC患者免疫治疗无效率为40.83%(49/120),1年死亡率为62.50%(75/120);无效组患者的血清miR-1298-5p表达显著低于有效组(P<0.05);死亡组患者的血清miR-1298-5p表达显著低于存活组(P<0.05).多因素非条件Logistic回归分析结果显示程序性死亡受体配体1阳性联合评分<5分为aNSCLC患者免疫治疗后死亡的独立危险因素,血清miR-1298-5p高表达为独立保护因素(P<0.05).血清miR-1298-5p表达预测aNSCLC患者免疫治疗无效和死亡的曲线下面积分别为0.796、0.816,敏感度分别为91.84%、64.00%,特异性分别为52.11%、84.44%.结论 aNSCLC患者血清miR-1298-5p低表达,与免疫治疗无效和死亡密切相关,可能成为aNSCLC患者免疫治疗效果及预后的辅助评估指标.
Objective To investigate the value of serum microRNA-1298-5p(miR-1298-5p)expression in evaluating efficacy and prognosis of immunotherapy in patients with advanced non-small cell lung cancer(aNSCLC).Methods A total of 120 aNSCLC patients who received immunotherapy at Ganzhou People's Hospital from January 2022 to April 2024 were selected and included in aNSCLC group,and 35 healthy individuals who came to the hospital for physical examination during the same period were included in control group.The aNSCLC patients were divided into ineffective group and effective group based on their 3-month immunotherapy efficacy,and into death group and survival group based on their 1-year follow-up prognosis.Multivariate unconditional Logistic regression analysis was performed to analyze the relationship between serum miR-1298-5p expression and immunotherapy prognosis in aNSCLC patients.Receiver operating characteristic curve analysis was used to assess the predictive efficacy of serum miR-1298-5p expression for immunotherapy response and prognosis in aNSCLC patients.Results The expression of serum miR-1298-5p in aNSCLC group was significantly lower than that in control group(P<0.05).Among 120 aNSCLC patients,immunotherapy inefficacy rate was 40.83%(49/120),and 1-year mortality rate was 62.50%(75/120).The expression of serum miR-1298-5p in ineffective group was significantly lower than that in effective group(P<0.05).The expression of serum miR-1298-5p in death group was significantly lower than that in survival group(P<0.05).The results of multivariate unconditional Logistic regression analysis showed that programmed death-ligand 1 combined positive score<5 was an independent risk factor for death after immunotherapy in aNSCLC patients,and high expression of serum miR-1298-5p was an independent protective factor(P<0.05).The area under the curve for serum miR-1298-5p expression in predicting immunotherapy inefficacy and death in aNSCLC patients was 0.796 and 0.816,with sensitivity of 91.84%and 64.00%,and specificity of 52.11%and 84.44%,respectively.Conclusion Serum miR-1298-5p expression is low in aNSCLC patients and is closely associated with inefficacy and death after immunotherapy.It may serve as an auxiliary indicator for assessing the efficacy and prognosis of immunotherapy in aNSCLC patients.
邓尘飞扬;陈雪娇;赖旭旺;赖景春
赣州市人民医院(南方医院赣州医院)肿瘤科,江西 赣州 341000赣州市肿瘤医院综合肿瘤内科,江西 赣州 341000赣州市人民医院(南方医院赣州医院)肿瘤科,江西 赣州 341000赣州市人民医院(南方医院赣州医院)肿瘤科,江西 赣州 341000
医药卫生
非小细胞肺癌晚期微RNA-1298-5p免疫治疗治疗效果预后
Non-small cell lung cancerAdvancedMicroRNA-1298-5pImmunotherapyTreatment efficacyPrognosis
《中国现代医生》 2026 (7)
16-20,5
江西省赣州市重点研发计划项目(GZ2024YLJ046)
评论